The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials.

<h4>Introduction</h4>Nintedanib can inhibit processes involved in the progression of fibrosis and can reduce the decline in forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF) and fibrotic-interstitial lung disease (fibrotic-ILDs). Although the adverse events assoc...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Chao-Hsien Chen, Hui-Chuan Lin, Ya-Hui Wang, Cheng-Yi Wang, You Shuei Lin, Chih-Cheng Lai
Format: article
Langue:EN
Publié: Public Library of Science (PLoS) 2021
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/84f6e65efae14b25b46260ce0671680e
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!